NEWRON PHARMACEUT. EO-20 (NP5) - Total Liabilities
Based on the latest financial reports, NEWRON PHARMACEUT. EO-20 (NP5) has total liabilities worth €51.15 Million EUR (≈ $59.80 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NEWRON PHARMACEUT. EO-20 - Total Liabilities Trend (2005–2025)
This chart illustrates how NEWRON PHARMACEUT. EO-20's total liabilities have evolved over time, based on quarterly financial data. See NP5 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
NEWRON PHARMACEUT. EO-20 Competitors by Total Liabilities
The table below lists competitors of NEWRON PHARMACEUT. EO-20 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Digital Imaging Technology INC
KQ:110990
|
Korea | ₩25.61 Billion |
|
Tong-Tai Machine Tool Co Ltd
TW:4526
|
Taiwan | NT$7.70 Billion |
|
Rossari Biotech Limited
NSE:ROSSARI
|
India | Rs8.36 Billion |
|
FS Bancorp Inc
NASDAQ:FSBW
|
USA | $2.89 Billion |
|
Berjaya Land Bhd
KLSE:4219
|
Malaysia | RM11.44 Billion |
|
Pinlive Foods Co Ltd
SHE:300892
|
China | CN¥241.21 Million |
|
Empresas Tricot S.A
SN:TRICOT
|
Chile | CL$199.32 Billion |
|
Armata Pharmaceuticals Inc
NYSE MKT:ARMP
|
USA | $295.48 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down NEWRON PHARMACEUT. EO-20's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NEWRON PHARMACEUT. EO-20 market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NEWRON PHARMACEUT. EO-20's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NEWRON PHARMACEUT. EO-20 (2005–2025)
The table below shows the annual total liabilities of NEWRON PHARMACEUT. EO-20 from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €51.15 Million ≈ $59.80 Million |
-18.09% |
| 2024-12-31 | €62.45 Million ≈ $73.01 Million |
+11.97% |
| 2023-12-31 | €55.77 Million ≈ $65.21 Million |
+8.88% |
| 2022-12-31 | €51.23 Million ≈ $59.89 Million |
+8.12% |
| 2021-12-31 | €47.38 Million ≈ $55.39 Million |
+39.55% |
| 2020-12-31 | €33.95 Million ≈ $39.69 Million |
+44.54% |
| 2019-12-31 | €23.49 Million ≈ $27.46 Million |
+354.97% |
| 2018-12-31 | €5.16 Million ≈ $6.04 Million |
-2.64% |
| 2017-12-31 | €5.30 Million ≈ $6.20 Million |
-22.52% |
| 2016-12-31 | €6.84 Million ≈ $8.00 Million |
-5.83% |
| 2015-12-31 | €7.27 Million ≈ $8.50 Million |
-6.98% |
| 2014-12-31 | €7.81 Million ≈ $9.13 Million |
-25.79% |
| 2013-12-31 | €10.53 Million ≈ $12.31 Million |
-38.21% |
| 2012-12-31 | €17.04 Million ≈ $19.92 Million |
+144.08% |
| 2011-12-31 | €6.98 Million ≈ $8.16 Million |
+0.58% |
| 2010-12-31 | €6.94 Million ≈ $8.11 Million |
-44.00% |
| 2009-12-31 | €12.39 Million ≈ $14.49 Million |
-15.85% |
| 2008-12-31 | €14.73 Million ≈ $17.22 Million |
+13.58% |
| 2007-12-31 | €12.97 Million ≈ $15.16 Million |
-29.13% |
| 2006-12-31 | €18.30 Million ≈ $21.39 Million |
+182.52% |
| 2005-12-31 | €6.48 Million ≈ $7.57 Million |
-- |
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more